Wealthspire Advisors LLC Has $4.73 Million Holdings in Stryker Corporation $SYK

Wealthspire Advisors LLC grew its stake in Stryker Corporation (NYSE:SYK) by 112.5% in the second quarter, HoldingsChannel reports. The fund owned 11,958 shares of the medical technology company’s stock after acquiring an additional 6,332 shares during the period. Wealthspire Advisors LLC’s holdings in Stryker were worth $4,731,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mid American Wealth Advisory Group Inc. bought a new position in Stryker in the 2nd quarter worth approximately $26,000. Sachetta LLC boosted its position in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Ridgewood Investments LLC increased its stake in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares during the period. MTM Investment Management LLC bought a new stake in shares of Stryker during the second quarter worth $38,000. Finally, Ransom Advisory Ltd bought a new stake in shares of Stryker during the first quarter worth $37,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 0.2%

Shares of NYSE:SYK opened at $359.53 on Wednesday. The company has a 50 day moving average price of $370.62 and a two-hundred day moving average price of $381.03. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market capitalization of $137.49 billion, a PE ratio of 47.62, a PEG ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the business earned $2.87 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the sale, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 522,453 shares of company stock worth $185,516,867 over the last ninety days. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on SYK. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Truist Financial raised their target price on shares of Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research note on Friday, November 14th. Evercore ISI dropped their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Barclays increased their price objective on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.